Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. (2022)
Attributed to:
Blood borne viruses
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2352-3018(22)00163-1
PubMed Identifier: 36055295
Publication URI: http://europepmc.org/abstract/MED/36055295
Type: Journal Article/Review
Volume: 9
Parent Publication: The lancet. HIV
Issue: 9
ISSN: 2352-3018